Soliris Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The soliris market size has grown strongly in recent years. It will grow from $2.03 billion in 2025 to $2.19 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to unmet needs in rare diseases, clinical success in pnh and ahus, regulatory orphan drug incentives, improved patient survival outcomes, limited therapeutic alternatives.

The soliris market size is expected to see strong growth in the next few years. It will grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to expansion into additional complement mediated diseases, rising rare disease awareness, growth in genetic diagnostics, increased healthcare funding for orphan drugs, long term therapy adherence programs. Major trends in the forecast period include rising adoption of complement inhibitor therapies, growing focus on ultra rare diseases, expansion of long term biologic treatment use, increased genetic testing for rare disorders, high value orphan drug market growth.

The rising prevalence of rare blood disorders is expected to drive the growth of the Soliris market in the coming years. Rare blood disorders are uncommon conditions that affect the blood’s production, components, or clotting, including hemophilia, sickle cell anemia, and thalassemia. The increasing prevalence of these disorders is attributed to better diagnostic methods, heightened awareness, and genetic and environmental factors. Soliris works by inhibiting the complement protein C5, helping patients with rare blood disorders by preventing excessive complement activation, which reduces the risk of severe complications such as hemolysis and organ damage, thereby improving overall disease management and patient outcomes. For example, in May 2024, the National Health Service (NHS) England reported that approximately 17,000 people in England are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. As a result, the growing prevalence of rare blood disorders is driving the Soliris market.

The increasing investment in rare disease research is also expected to boost the growth of the Soliris market. The surge in funding for rare disease research is driven by the growing recognition of unmet medical needs, advances in genomics, and the potential for breakthrough therapies that improve patient outcomes. Such investment supports Soliris by expanding knowledge of underserved conditions, leading to greater demand for effective treatments. For example, in July 2023, the UK Department of Health and Social Care provided significant funding, including USD 834.2 million (£790 million) for Biomedical Research Centers, USD 15.06 million (£12 million) for the UK Rare Disease Research Platform, and USD 50.2 million (£40 million) for the NIHR BioResource, which connects genetic data to clinical traits across 50 rare diseases to enhance diagnostics and treatment development. Consequently, the growing investment in rare disease research is driving the Soliris market.

A key trend in the Soliris market is the focus on developing biologic therapies for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment options for rare blood disorders. This represents a notable advancement in managing NMOSD, a rare and debilitating autoimmune disease of the central nervous system, by offering an effective therapy that reduces relapses and prevents further neurological damage. For instance, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, obtained approval for Soliris (eculizumab) from China’s National Medical Products Administration (NMPA) to treat adult patients with NMOSD who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This approval made Soliris the first and only complement inhibitor authorized for NMOSD treatment in China.

Major companies operating in the soliris market are Pfizer.

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the soliris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the soliris market by increasing costs associated with monoclonal antibody production inputs, infusion delivery systems, and cold chain logistics. These impacts are particularly evident in regions reliant on imported orphan biologics such as asia pacific and parts of europe. Hospital procurement costs have risen, affecting reimbursement negotiations. However, tariffs have encouraged localized biologics manufacturing investments. This supports long term access and supply continuity for rare disease treatments.

The soliris market research report is one of a series of new reports that provides soliris market statistics, including soliris industry global market size, regional shares, competitors with a soliris market share, detailed soliris market segments, market trends and opportunities, and any further data you may need to thrive in the soliris industry. This soliris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Soliris (Eculizumab) is a monoclonal antibody developed by Alexion Pharmaceuticals that inhibits the complement protein C5, helping to reduce inflammation and tissue damage caused by an overactive immune system. It is primarily indicated for rare diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).

The main forms of Soliris include plasma exchange and plasma infusion. Plasma exchange is a procedure that removes and replaces a patient’s plasma to treat conditions such as autoimmune and blood disorders. Soliris is used for applications in PNH and aHUS and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The soliris market consists of sales of soliris (eculizumab) 300 mg/30 mL vial, soliris (eculizumab) injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.